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Purpose: Investigation of drug safety signals is one of the major tasks in
pharmacovigilance. Among many potential signals identified, only a few reflect
adverse drug reactions requiring regulatory actions, such as product information (PI)
update. Limited information is available regarding the signal characteristics that might
predict PI update following signal evaluation. The objective of this study was to iden-
tify signal characteristics associated with PI updates following signal evaluation by the
European Medicines Agency Pharmacovigilance Risk Assessment Committee during
2012 to 2016.
Methods: A comparative study was performed based on data from 172 safety sig-
nals. Characteristics of signals were extracted from the European Pharmacovigilance
Issues Tracking Tool database. Multivariable logistic regression analysis was used to
assess the relationship between signal characteristics and the decision to update
the PI.
Results: Multivariable logistic regression analysis showed that the presence of evi-
dence in multiple types of data sources (adjusted odds ratio [OR] 7.8 95% CI [1.5,
40.1]); mechanistic plausibility of the drug‐event association (adjusted OR 3.9 95%
CI [1.9, 8.0]); seriousness of the event (adjusted OR 4.2 95% CI [1.3, 13.9]); and age
of drugs ≤5 years (adjusted OR 3.9 95% CI [1.2, 12.7]) were associated with the deci-
sion to change the PI (P < 0.05).
Conclusions: This study identified 4 characteristics of drug safety signals that have
shown to be associated with PI changes as outcome of signal evaluation. These char-
acteristics may be used as criteria for selection and prioritization of potential signals
that are more likely to necessitate product information updates.
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KEY POINTS
• Studies investigating drugs safety signals characteristics
that might predict safety‐related product information
changes are lacking.
• Confirmation of the signals in multiple types of data
sources, the presence of mechanistic plausibility of a
drug‐event association, seriousness of the events, and
age of drugs ≤5 years were associated with the
decision to update the product information.
• These criteria may be used for the selection or
prioritization of the signals that are more likely to
provide new safety information.
2 INSANI ET AL.1 | INTRODUCTION
During the development of medicinal products, identification of
adverse reactions, particularly rare adverse reactions and those with
long latency, is limited. Pre‐approval trials are typically conducted with
relatively small number of patients in a limited length of time. Selective
enrollment of participants may also limit the generalizability in the
postmarketing environment. Continuous safety surveillance is thus
essential to ensure patient safety.1-3
A safety signal is defined as the information suggesting a new
potential association or new aspects of a known association between
medicines and adverse event(s) that warrant further investigation.4
Signals can be generated from a wide range of sources, eg, a review
of spontaneous case reports, data from active surveillance system, or
from literature findings. To assess whether the signals represent true
risks associated with medicines, several steps of additional data collec-
tion and analysis should be conducted. Based on such assessment,
appropriate actions should be decided upon, eg, regulatory actions,
such as amendment of product information (PI), initiation of referral,
urgent safety restrictions; additional data needed, such as post‐autho-
rization safety studies; and no actions needed beside routine
pharmacovigilance.5
In the European Union, the decision‐making process related to
safety signals is coordinated by the European Medicines Agency
(EMA) Pharmacovigilance Risk Assessment Committee (PRAC).6 The
PRAC is responsible for recommendations following signal assess-
ment. During the first 18 months since its operation, 59% of the sig-
nals discussed at the PRAC resulted in regulatory actions, mostly
updates of safety‐related information in the PI.7 Such amendments
can include the addition of adverse drug reaction (ADR) or new aspect
of current ADR, contraindication, warning and precaution related to
the drug safety, etc.8
Several signal characteristics have been postulated to help in sig-
nal assessment, including strength of evidence, public health impact,
and the novelty of drugs and/or safety issues.9-12 However, informa-
tion on the predictive validity of these criteria, ie, whether they can
predict if the safety signal reviewed requires a PI update is lacking.
Therefore, we conducted this study to identify signal characteristics
associated with the decision to update the PI following the signal
assessment.2 | METHODS
The list of safety signals discussed at the PRAC since September 2012
until May 2016 was obtained from the publicly available data on the
website of the EMA.13We included signals which resulted in PI updates
and those which were closed with no PI update or other regulatory
actions. The signals with no assessment conclusion available at the time
of data collection was excluded because the assessment was still ongo-
ing. Signals that were further assessed in other regulatory procedures
and those which resulted in regulatory actions other that PI updates
were excluded. Each signal comprised information on the adverse event
and the suspected drug. The adverse events were classified using the
Medical Dictionary for Regulatory Affairs (MedDRA) 19.1 based onthe System Organ Classification (SOC) code.14 The suspected drugs
were categorized based on the Anatomical Therapeutic Chemical
(ATC) classification codes by the World Health Organization (WHO).15
Signals characteristics were extracted from the European
Pharmacovigilance Issues Tracking Tool (EPITT) database. EPITT is a
web‐based system facilitating the tracking and sharing of safety infor-
mation on medicinal products for human use established by the EMA.162.1 | Signals characteristics
Characteristics that are potentially important during signal assess-
ment were pre‐defined and classified in 3 categories, namely the
strength of evidence, public health impact, and the novelty of
the drug. The rationale and definitions used for categorization
of the signals are provided below.
2.1.1 | Characteristics related to the strength of
evidence
• Source of evidence
The presence of signals in a wide range of additional sources may
strengthen the evidence supportive of the signals.17,18 For each signal,
we extracted the type of data source providing supporting evidence
for possible causal association between the drug and the event, ie,
spontaneous case reports, observational studies, clinical studies, and
pre‐clinical studies.
• Mechanistic plausibility
The presence of mechanistic plausibility is an important factor
supporting the association.18 Mechanistic plausibility was considered
available when either a hypothesized or established mechanism was
discussed during signal evaluation.
• Presence of disproportionate reporting
Increased frequencies of the case reports concerning a specific
drug‐event association in comparison with general reporting frequen-
cies may indicate a new potential signal.17,19,20 The signals were
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dence interval of proportional reporting ratio (PRR) was equal or
greater than one.5 (2) The value of Empirical Bayes Geometric Mean
(EBGM) was equal or greater than 2.5.21
• Positive dechallenge or rechallenge
The presence of positive dechallenge and rechallenge might be
important in establishing causality based on individual narratives of
the reported cases. 20,22 Positive dechallenge was considered present
if there was at least 1 spontaneous post‐marketing report where the
adverse event disappeared after the concerned drug was withdrawn.
Positive rechallenge was noted as present if the assessment of a signal
included at least 1 report where the adverse event reappeared after
restarting the drug.
• Possible class effect
Knowledge that drugs from the same pharmacological class
produce the same adverse effect might strengthen the evidence for
a signal. The signals were classified as reflecting possible class effects
if during signal assessment it was mentioned that the suspected event
is labeled for other drugs from the same class.22TABLE 1 Adverse event and suspected drug of included signals
n (%)
Adverse events (SOC)
Skin and subcutaneous tissue disorders 18 (11)2.2 | Criteria related to the public health impact
2.2.1 | Seriousness of the events
Serious events usually have an increased public health importance
compared with non‐serious ones.18,23 The events were classified as
serious if they were included in the EMA's important medical events
list. This list includes medical events that are fatal, life‐threatening,
require hospitalization or prolong existing hospitalization, result in
significant disability, or cause congenital anomaly/birth defect.24
2.2.2 | Criteria related to drug novelty
New risks are more likely to be observed in newer drugs.9,12 The age of a
drug was calculated from the date of the first authorization until the date
when the PRAC recommendation was made.25 The drugs were grouped
in the following age categories: 0 to 5; 5 to 10; 10 to 15; and ≥15 years.General disorders and administration site condition 15 (9)
Blood and lymphatic system disorders 12 (7)
Nervous system disorders 12 (7)
Metabolism and nutrition disorders 11 (6)
Cardiac disorders 11 (6)
Gastrointestinal disorders 10 (6)
Others (less than 5%) 83 (48)
Drugs class
Antineoplastic and immunomodulating agents 53 (31)
Nervous system 30 (17)
Antiinfective for systemic use 22 (13)
Alimentary tract and metabolism 14 (8)
Cardiovascular system 13 (8)
Blood and blood forming organs 11 (6)
Others (less than 5%) 29 (17)3 | DATA ANALYSIS
Descriptive analysis was used to compare characteristics of signals
between the groups which resulted in safety‐related PI changes and
without. To assess the influence of various characteristics on the PI
update, first, a univariate logistic regression analysis was performed.
Criteria that were associated with PI changes with a P‐value<0.1 in
the first analysis were then included in a multivariate logistic regres-
sion model. Subgroup analysis was performed to investigate whether
different signal characteristics were associated with the updates of
section 4.8 (undesirable effects) as compared with updates of
section 4.4 (special warnings and precautions for use) of the PI. The
results were expressed as odds ratios (ORs) with 95% confidence
intervals (CIs). P < 0.05 defined statistical significance in the mainanalysis, while for subgroup analysis, statistical significance was set
at P < 0.1. Analysis was performed using Stata 11.2.4 | RESULTS
During the study period (September 2012–May 2016), 300 signals were
assessed at the PRAC. After excluding non‐eligible signals, ie, signals
which were further investigated in other regulatory procedures
(n = 94), signals which resulted in regulatory actions other than PI
updates (n = 20), signals assessments were still ongoing (n = 4), and sig-
nals for which a full assessment could not be retrieved (n = 10), 172 sig-
nals remained for the analysis. The most frequently identified ADR were
related to skin and subcutaneous tissue disorders (10%). Most fre-
quently involved drugs were antineoplastic and immunomodulating
drugs (31%) (Table 1). A total of 101 signal assessments resulted in PI
updates, and 71 were assessed and closed with no actions beside rou-
tine pharmacovigilance. Most PI updates involved the revision of the
ADR section (section 4.8), followed by the warnings and precautions
section (section 4.4). Updates resulted from a signal could involve the
revision of more than 1 PI sections (Figure 1).
Spontaneous case reports were the most common source of evi-
dence, supporting 87% of the signals. We also found that 43% of the
signals which resulted in PI updates were assessed based on evi-
dence coming from spontaneous case reports only. In the univariate
logistic regression model, the presence of evidence from spontane-
ous case reports was associated with PI update (unadjusted OR 2.2
[95% CI 0.9, 5.6]). Greater magnitude of difference was seen in the
signals supported by ≥3 types of sources (unadjusted OR 7.4
[95%CI 1.6, 33.3]). The presence of biological plausibility of the
drug‐event association led to more PI updates (unadjusted OR 4.2
[95% CI 2.2, 8.0]).
Although the proportion of positive dechallenge and rechallenge
results was higher among the signals resulted in PI updates, the
FIGURE 1 Section of product information
updated following safety signal evaluation by
the PRAC during September 2012 to May
2016
TABLE 2 Univariate analysis comparing characteristics of signals with and without PI update
Characteristics
Signals Resulted in
PI Update (n = 101 (%))
Signals were Closed with no





Case reports 92 (61) 58 (39) 2.2 (0.9, 5.6) 0.07
Observational studies 24 (56) 19 (44) 0.8 (0.4, 1.7) 0.65
Clinical studies 38 (62) 23 (38) 1.2 (0.6, 2.3) 0.48
Pre‐clinical studies 18 (72) 7 (28) 1.9 (0.7, 5.0) 0.15
≥ 2 sources 50 (60) 33 (40) 1.1 (0.6, 2.0) 0.69
≥ 3 sources 18 (90) 2 (10) 7.4 (1.6, 33.3) 0.00
Mechanistic plausibility 74 (73) 28 (27) 4.2 (2.2, 8.0) 0.00
Disproportionate reporting 40 (56) 31 (44) 0.8 (0.4, 1.5) 0.59
Presence of dechallenge/rechallenge results
Positive dechallenge 36 (61) 23 (39) 1.1 (0.6, 2.1) 0.65
Positive rechallenge 34 (65) 18 (35) 1.4 (0.2, 7.6) 0.24
Possibility of a class effect 14 (67) 7 (33) 1.4 (0.5, 3.8) 0.43
Public health impact
Seriousness of the event 95 (61) 60 (39) 2.9 (1.0, 8.2) 0.04
Novelty
Age of drugs
0–5 years old 16 (76) 5 (24) 2.4 (0.8, 7.1) 0.09
6–10 years old 12 (44) 15 (56) 0.5 (0.2, 1.1) 0.10
10–15 years old 19 (59) 13 (41) 1.0 (0.4, 2.2) 0.93
>15 years old 54 (59) 38 (41) 0.9 (0.5, 1.8) 0.99
The bold data are the criteria with P‐ value < 0.1 in univariate analysis, which were then included in multivariate logistic regression model
4 INSANI ET AL.differences were not statistically significant. The proportion of serious
events was significantly higher among the signals resulted in PI update
(unadjusted OR 2.9 [95% CI 1.0, 8.2]). Signals concerning younger
products, ie, ≤ 5 years old, resulted more often in PI updates (unad-
justed OR 2.4 [95% CI 0.8, 7.1]) (Table 2).
In the multivariate logistic regression model, 4 signals characteris-
tics were shown to be independently associated with PI update, ie, the
presence of evidence in ≥3 types of sources (adjusted OR 7.8 [95% CI
1.5, 40.1]), the mechanistic plausibility of drug‐event association
(adjusted OR 3.9 [95% CI 1.9, 8.0]), seriousness of the events(adjusted OR 4.2 [95% CI 1.3, 13.9]), and age of drugs ≤5 years
(adjusted OR 3.9 [95% CI 1.2, 12.7]) (Table 3).
Based on the subgroup analysis where signals resulting in update
of section 4.4 were compared with signals resulting in update of
section 4.8, the seriousness of the event, disproportional reporting,
and age of the drug being 0 to 5 years old were associated with an
update of section 4.4, but not section 4.8. On a contrary, the avail-
ability of a positive dechallenge and rechallenge, the possibility of a
class effect, and presence of evidence in ≥3 types of sources were
associated with an update of section 4.8 but not section 4.4. The




Signals supported by case reports 1.6 (0.5, 4.4) 0.34
Signals supported by ≥3 types of sources 7.8 (1.5, 40.1) 0.01
Mechanistic plausibility 3.9 (1.9, 8.0) 0.00
Seriousness of the event 4.2 (1.3, 13.9) 0.01
Age of drugs ≤5 years 3.9 (1.2, 12.7) 0.02
The bold data are the criteria with P value <0.1 in a multivariate logistic regression model
INSANI ET AL. 5drugs in older age category (6–10 years) were less likely to be asso-
ciated with any PI updates (Table 4).
5 | DISCUSSION
In this study, we examined several drug safety signals characteristics
that might predict ADR requiring PI update. We found that the pres-
ence of evidence in multiple types of data sources, mechanistic plausi-
bility of event‐drug association, seriousness of the event, and age of
drugs ≤5 years old were associated with the decision to update the PI.
Spontaneous case reports remain an important source of ADR
detection. Spontaneous reports often contain essential information
necessary for causality assessment not available in other sources of
data, such as plausible time course for development of ADR following
initiation of the drug and information on dechallenge and rechal-
lenge.26 However, we found that there was no distinct type of data
source that was independently associated with signals requiring PITABLE 4 Subgroup analysis comparing characteristics of signals resulting
Characteristics
Crude Odds Ratio (95% CI), P‐Value
Signals Resulted in Update
of Section 4.4 (n = 13)
Strength of evidence
Source of evidence
Case reports 1.3 (0.2, 6,7), P = 0.71
Observational studies 1.2 (0.3, 4.4), P = 0.76
Clinical studies 1.3 (0.3, 4.4), P = 0.67
Pre‐clinical studies 0.7 (0.1, 6.7), P = 0.80
≥ 2 sources 1.3 (0.4, 4.3), P = 0.62
≥ 3 sources 2.8 (0.2, 34.2), P = 0.40
Mechanistic plausibility 8.4 (1.7, 41.0), P = 0.00
Disproportionate reporting 0.2 (0.04, 1.1), P = 0.07
Presence of de−/rechallenge results
Positive dechallenge 0.3 (0.1, 1.8), P = 0.23
Positive rechallenge 0.2 (0.02, 2.0), P = 0.19
Possibility of a class effect 1.6 (0.3, 9.0), P = 0.55
Public health impact
Seriousness of the event 4.3 (1.1,16), P = 0.03
Novelty
Age of drugs
0–5 years old 3.96 (0.8, 19.1), P = 0.08
6–10 years old 0.3 (0.03, 2.5), P = 0.28
10–15 years old 1.3 (0.3, 5.5), P = 0.68
>15 years old 0.7 (0.2, 2.4), P = 0.62
The bold data are the criteria with P‐value < 0.1 which were considered influeupdates. It is rather the replication of the signal in multiple additional
data sources that might indicate stronger evidence, as confirmed in
our study. This finding is comparable with previous studies showing
that multiple evidence sources supported the decision to conduct reg-
ulatory actions, eg, Food and Drug Administration safety labeling
changes and drugs withdrawals in France.27,28 Multiple evidence
sources was also one of the criteria employed in the safety signals pri-
oritization framework developed by several institutions.11,29
Another criterion significantly associated with a PI update is the
presence of a mechanistic plausibility of the drug‐event association,
either an established or a hypothesized mechanism. Some true safety
signals did not include a confirmed mechanism, but the occurrence of
adverse events was mechanistically plausible, providing additional evi-
dence supportive of the association. In addition, we also found that in
several signal assessments, unlikeliness of a mechanistic plausibility
constituted one of the arguments to reject the signals, eg, in the signal
of glioblastoma and other brain neoplasms related to adalimumab andin update of section 4.4, 4.8, and both sections
Signals Resulted in Update of
Section 4.8 (n = 40)
Signals Resulted in Update
of Both Sections (n = 37)
3.1 (0.8, 11.2), P = 0.09 8.8 (1.1, 70.1), P = 0.04
0.6 (0.2, 1.7), P = 0.42 1.0 (0.4, 2.4), P = 0.97
1.2 (0.5, 2.8), P = 0.58 1.4 (0.6, 3.2), P = 0.40
2.2 (0.7, 6.8), P = 0.14 2.5 (0.8, 7.6), P = 0.10
1.0 (0.4, 2.2), P = 0.91 1.5 (0.6, 3.3), P = 0.31
10.0 (2.20, 49.1), P = 0.00 9.5 (1.9, 47.5), P = 0.00
2.5 (1.1, 5.6), P = 0.02 4.7 (1.9, 11.6), P = 0.00
1.1 (0.4, 2.3), P = 0.89 1.1 (0.4, 2.4), P = 0.82
2.0 (0.9, 4.6), P = 0.07 0.8 (0.3, 2.1), P = 0.77
3.2 (1.4, 7.3), P = 0.00 1.4 (0.5, 3.3), P = 0.43
2.6 (0.9, 7.7), P = 0.07 0.5 (0.1, 2.6), P = 0.43
2.2 (0.8, 6.2), P = 0.10 2.2 (0.8, 6.1), P = 0.12
1.1 (0.2, 4.7), P = 0.92 2.0 (0.5, 7.6), P = 0.27
0.9 (0.3, 2.4), P = 0.88 0.2 (0.04, 0.9), P = 0.04
1.1 (0.4, 2.9), P = 0.82 0.8 (0.2, 2.4), P = 0.78
0.8 (0.3, 1.8), P = 0.72 1.2 (0.5, 2.8), P = 0.55
ntial in subgroup analysis
6 INSANI ET AL.infliximab. Due to the size of their molecules, it was considered
unlikely that these products would cross the blood brain barrier and
caused malignancies in the brain.30
Seriousness of the event was another independent predictor of PI
update in our analysis. Many serious events addressed by the PRAC in
the recent years concerned events included on the Designated Medical
Event term list, which are by definition serious events that are in general,
more likely to be caused by drugs.31 Therefore, the selection of signals
discussed in the PRAC might have been initially skewed towards more
serious events, as confirmed by the fact that majority of the signals
included in the analysis were serious events. Our finding was comparable
with previous study by Puijenbroek et al showing that seriousness of
the adverse event was a determinant during signals selection process.9
Serious reports might possess greater public health importance, provid-
ing the signals the precedence to be prioritized for evaluation.
In the subset analysis, the seriousness of the event was associated
with the update of section 4.4, but not section 4.8. This implies that seri-
ous events may bemore likely to prompt inclusion of a warning to inform
health care professionals about a serious and potentially life‐threatening
event; however, if there is sufficient evidence of causal association
between an event and a drug, the adverse event will be included in the
section 4.8 (undesirable effects) regardless of the seriousness.
We found that signals concerning newer products (≤ 5 years old)
resulted more often in PI updates. At the time of drugs approval, only
partial safety information was obtained due to several known limita-
tions in pre‐marketing clinical studies.1-3 The rapid use of drugs by
larger and more diverse population might contribute to the detection
of new ADR during the first years after drugs approval. In addition,
younger drugs are more intensively monitored by the regulatory
authorities, eg, through a more frequent cycle for PSUR, which may
also contribute to the detection of new safety issues. Besides, it has
been shown by Weber that adverse reaction reporting peaks at the
end of second year after authorization, ie, the so‐called Weber effect
theory.32 Another study performed by McAdams et al also showed
that during the first year after approval, the highest reporting of
adverse event trend was observed.33 The subset analysis showed that
the signals concerning very new products (≤5 years old) were associ-
ated with update of section 4.4, while the signals for somewhat older
products (6‐10 years old) are less likely to be associated with any PI
updates. On the other hand, we also found that more than half
(59%) of the signals that resulted in PI updates concerned products
that have been in the market for more than 15 years. PI updates in
these cases were probably due to accumulation of evidence from dif-
ferent sources over the time. This finding highlights again the impor-
tance of continued pharmacovigilance for more mature products.7
Although positive dechallenge and rechallenge observed in indi-
vidual spontaneous reports are important factors in establishing cau-
sality,20,22 their presence was not a decisive factor for PI update in
general. In the subset analysis, however, both positive dechallenge
and rechallenge were associated with update of section 4.8 (as
opposed to update of section 4.4). This could be explained by the fact
that clinically meaningful dechallenge and rechallenge, especially when
combined with other aspects of the narrative, eg, information regard-
ing medical history of the patient, time to onset, the use of concomi-
tant drugs, etc, are strongly suggestive of causal association andtherefore signals with reported positive dechallenge and rechallenge
are more likely to result in update of section 4.8.34,35 The presence
of positive dechallenge and rechallenge was however not associated
with update of section 4.4, probably because a well‐established causal
association is neither sufficient nor necessary for inclusion of a
warning for health care providers in section 4.4 of PI. For example,
common, non‐serious adverse events with well‐established causality
may not require a special warning, while life‐threatening adverse
events requiring a prompt action on behalf of prescribers to prevent
irreversible harm in patients may warrant inclusion of a warning in
section 4.4 even if available evidence is limited.
Our study showed that the presence of disproportionate
reporting in safety databases was not necessarily associated with the
decision to update the PI. Disproportionality analysis is subject to
well‐known limitations, such as limited database quality inherent in
voluntary reporting system, various confounding factors, and inability
to provide actual denominator, ie, number of subjects who consumed
drug of interest. These limitations might contribute to the occurrence
of false signal of disproportionate reporting or alternatively true safety
signals may appear without disproportional reporting.34-38 However,
in the subset analysis, the presence of disproportionate reporting
was associated with the update of section 4.4, implying serious events
were probably often reported disproportionately.39
There have been a few attempts to combine criteria for signal prior-
itization in algorithms or frameworks to support the drug signal selec-
tion and prioritization process by different organizations responsible
in managing drug safety issues.10 Enhancement of such decision sup-
port frameworks with valid predictive criteria may increase their accu-
racy. Our study provides a set of variables which show predictive
value that can be incorporated in such frameworks to support the deci-
sion making when dealing with a large number of potential signals.
The strength of our study is that it is the first study investigating
the predictive value of drug safety signals characteristics in terms of
predicting whether the signals represent ADR requiring PI updates.
In addition, we included signals investigated during the first 3.8 years
since the establishment of the PRAC. Nevertheless, this study also had
some limitations. We did not include signals addressed in other regu-
latory procedures, eg, the PSUR assessment procedure. However,
because it was considered that the conduct of assessment was rela-
tively similar, no significant change is expected. Furthermore, the per-
formance of these characteristics is based on the signal assessment
performed in the European Union. These criteria may perform differ-
ently in other databases comprising safety evaluation conducted in
other geographic regions. Therefore, further studies are recommended
if these variables are to be used in a different setting.6 | CONCLUSIONS
Our study highlighted that the presence of evidence in multiple type of
sources, mechanistic plausibility, seriousness of the event, and age of
drugs ≤5 years were the predictors of safety‐related PI changes. The
characteristics related to the strength of evidence were particularly
important for the update of section 4.8 (undesirable effects), while
seriousness of the event was an important criteria for the changes in
INSANI ET AL. 7section 4.4 (warning and precaution for use). The knowledge related to
these factors may be used to improve selection and prioritization of
potential signals that are more likely to provide new safety information.ETHICS STATEMENT
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